Ligand Pharmaceuticals Incorporated (LGND) - Stock Analysis
Last updated: Sep 20, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠Ample Liquidity ⢠Rising Debt LGND offers exceptional profitability and liquidity, but rising leverage, low asset efficiency, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Recent rebound ⢠Range support ⢠Resistance test Support Level: $275â$280 Resistance Level: $285â$290 LGND is attempting to stabilize after rebounding from $275.20, but it needs to clear $285â$290 to confirm a stronger recovery, while a break below $275 would renew downside risk.
Sentiment & News
Key News Insights: ⢠XOMA-driven royalties ⢠$700M capital ⢠Share-price weakness Ligand's royalty-growth strategy and capital deployment prospects remain promising, but a 10% share decline highlights near-term investor caution.
AI Summary
LGND's XOMA acquisition and convertible financing transform it into a leveraged royalty-capital allocator, making successful, accretive deployment of its enlarged capital baseânot legacy 95% marginsâthe decisive investment test; investors should demand evidence of XOMA-driven cash-flow and ROIC growth before underwriting its premium valuation.
Description
Ligand Pharmaceuticals develops or acquires technologies that support pharmaceutical companies in discovering and developing medicines, commercializing a portfolio that spans oncology, infectious disease, endocrine and bone health, vaccines, and other specialty treatments. The company also partners on and licenses programs in clinical development targeting cancer, neurological, metabolic, cardiovascular, and other conditions, and it manufactures Captisol excipient materials. Founded in 1987, Ligand is headquartered in Emeryville, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 28 | May 5 | LGND | Ligand Pharmaceuticals Incorporated | Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50. | Closed | -0.0% |